177 related articles for article (PubMed ID: 28786079)
1. JSH guideline for tumors of hematopoietic and lymphoid tissues: leukemia 1. Acute myeloid leukemia (AML).
Miyawaki S
Int J Hematol; 2017 Sep; 106(3):310-325. PubMed ID: 28786079
[No Abstract] [Full Text] [Related]
2. JSH guideline for tumors of hematopoietic and lymphoid tissues: leukemia: 2. Acute promyelocytic leukemia (APL).
Asou N; Fujita H; Shinagawa K
Int J Hematol; 2017 Oct; 106(4):459-470. PubMed ID: 28856623
[No Abstract] [Full Text] [Related]
3. Attempts to optimize postinduction treatment in childhood acute myeloid leukemia without core-binding factors: A report from the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG).
Hasegawa D; Tawa A; Tomizawa D; Watanabe T; Saito AM; Kudo K; Taga T; Iwamoto S; Shimada A; Terui K; Moritake H; Kinoshita A; Takahashi H; Nakayama H; Koh K; Goto H; Kosaka Y; Miyachi H; Horibe K; Nakahata T; Adachi S
Pediatr Blood Cancer; 2020 Dec; 67(12):e28692. PubMed ID: 32886449
[TBL] [Abstract][Full Text] [Related]
4. [Current therapy for acute myeloid leukemia and acute promyelocytic leukemia].
Miyawaki S
Rinsho Ketsueki; 2014 Jan; 55(1):31-41. PubMed ID: 24492035
[No Abstract] [Full Text] [Related]
5. Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemia.
De Astis E; Clavio M; Raiola AM; Ghiso A; Guolo F; Minetto P; Galaverna F; Miglino M; Di Grazia C; Ballerini F; Marani C; Pastori G; Mitscheunig L; Cruciani F; Lovera D; Varaldo R; Ghiggi C; Lemoli RM; Bacigalupo A; Gobbi M
Ann Hematol; 2014 Dec; 93(12):2011-8. PubMed ID: 24989345
[TBL] [Abstract][Full Text] [Related]
6. High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial.
Willemze R; Suciu S; Meloni G; Labar B; Marie JP; Halkes CJ; Muus P; Mistrik M; Amadori S; Specchia G; Fabbiano F; Nobile F; Sborgia M; Camera A; Selleslag DL; Lefrère F; Magro D; Sica S; Cantore N; Beksac M; Berneman Z; Thomas X; Melillo L; Guimaraes JE; Leoni P; Luppi M; Mitra ME; Bron D; Fillet G; Marijt EW; Venditti A; Hagemeijer A; Mancini M; Jansen J; Cilloni D; Meert L; Fazi P; Vignetti M; Trisolini SM; Mandelli F; de Witte T
J Clin Oncol; 2014 Jan; 32(3):219-28. PubMed ID: 24297940
[TBL] [Abstract][Full Text] [Related]
7. [Acute myeloid leukemia trials by Japan Adult Leukemia Study Group (JALSG)].
Miyazaki Y
Rinsho Ketsueki; 2009 Aug; 50(8):611-6. PubMed ID: 19915375
[No Abstract] [Full Text] [Related]
8. Acute myeloid leukemia.
Rubnitz JE; Gibson B; Smith FO
Pediatr Clin North Am; 2008 Feb; 55(1):21-51, ix. PubMed ID: 18242314
[TBL] [Abstract][Full Text] [Related]
9. Fractionated gemtuzumab ozogamicin combined with intermediate-dose cytarabine and daunorubicin as salvage therapy in very high-risk AML patients: a bridge to reduced intensity conditioning transplant?
Paubelle E; Ducastelle-Leprêtre S; Labussière-Wallet H; Nicolini FE; Barraco F; Plesa A; Salles G; Wattel E; Thomas X
Ann Hematol; 2017 Mar; 96(3):363-371. PubMed ID: 28011984
[TBL] [Abstract][Full Text] [Related]
10. Hydroxyurea prior to intensive chemotherapy in AML with moderate leukocytosis.
Bertoli S; Tavitian S; Picard M; Huguet F; Vergez F; Delabesse E; Sarry A; Bérard E; Récher C
Leuk Res; 2018 Dec; 75():7-10. PubMed ID: 30419550
[No Abstract] [Full Text] [Related]
11. Anthracycline-based consolidation may determine outcome of post-consolidation immunotherapy in AML.
Aurelius J; Möllgård L; Kiffin R; Ewald Sander F; Nilsson S; Thorén FB; Hellstrand K; Martner A
Leuk Lymphoma; 2019 Nov; 60(11):2771-2778. PubMed ID: 30991860
[TBL] [Abstract][Full Text] [Related]
12. Current and emerging therapies for acute myeloid leukemia.
Robak T; Wierzbowska A
Clin Ther; 2009; 31 Pt 2():2349-70. PubMed ID: 20110045
[TBL] [Abstract][Full Text] [Related]
13. Diffuse osteosclerosis-associated acute myeloid leukemia.
Ward DE; Fondaw MB; Shroff SK; Reddy VS; Khaled YA
J Clin Oncol; 2012 Jan; 30(1):e3-4. PubMed ID: 22124108
[No Abstract] [Full Text] [Related]
14. Important milestones in acute leukemia in 2013.
Rowe JM
Best Pract Res Clin Haematol; 2013 Sep; 26(3):241-4. PubMed ID: 24309524
[TBL] [Abstract][Full Text] [Related]
15. [Standard therapies for acute myeloid leukemia].
Matsumura I
Rinsho Ketsueki; 2009 Oct; 50(10):1389-400. PubMed ID: 19915347
[No Abstract] [Full Text] [Related]
16. [Treatment of acute myeloid leukemia -- a single center experience (2007-2013)].
Selmeczi A; Udvardy M; Illés A; Telek B; Kiss A; Batár P; Reményi G; Szász R; Ujj Z; Márton A; Ujfalusi A; Hevessy Z; Pinczés L; Bedekovics J; Rejtő L
Orv Hetil; 2014 Apr; 155(17):653-8. PubMed ID: 24755447
[TBL] [Abstract][Full Text] [Related]
17. Relapsed acute myeloid leukemia: why is there no standard of care?
Ravandi F
Best Pract Res Clin Haematol; 2013 Sep; 26(3):253-9. PubMed ID: 24309527
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of extramedullary relapses is higher after allogeneic stem cell transplantation than after chemotherapy in adult patients with acute myeloid leukemia.
Shimizu H; Saitoh T; Hatsumi N; Takada S; Handa H; Jimbo T; Sakura T; Miyawaki S; Nojima Y
Leuk Res; 2013 Nov; 37(11):1477-81. PubMed ID: 24054717
[TBL] [Abstract][Full Text] [Related]
19. Cytosine arabinoside and daunorubicin induction therapy in a patient with acute myeloid leukemia on chronic hemodialysis.
Krashin E; Dolberg OJ; Hellmann I; Huitema AD; Rosing H; Ellis M
Anticancer Drugs; 2016 Sep; 27(8):800-3. PubMed ID: 27254285
[TBL] [Abstract][Full Text] [Related]
20. Association between the secondary colony-plating efficiency of blast progenitors and the remission induction outcome of acute myeloblastic leukemia patients.
Nara N
Nihon Ketsueki Gakkai Zasshi; 1988 Dec; 51(8):1624-9. PubMed ID: 3247826
[No Abstract] [Full Text] [Related]
[Next] [New Search]
